Drugs / PSMA-TTC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03724747 | Dec 2018 → Aug 2022 | prostate carcinoma | Bayer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-06 | Bayer | Results Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021 bayer.com ↗
A featured presentation will highlight the PSMA-TTC BAY 2315497, targeting prostate specific membrane antigen (PSMA) in prostate cancer cells, showing synergistic anti-tumor activity in combination with PARP inhibitor olaparib in preclinical prostate cancer models. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-06 | Bayer | Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021 bayer.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSMA-TTC | “We describe a novel, antibody-based TAT, the PSMA-targeted thorium-227 conjugate PSMA-TTC (BAY 2315497) consisting of the alpha-particle emitter thorium-227 complexed by a...” PMID 31831560 ↗ Dec 2019 |
| Known as | BAY 2315497 | “We describe a novel, antibody-based TAT, the PSMA-targeted thorium-227 conjugate PSMA-TTC (BAY 2315497) consisting of the alpha-particle emitter thorium-227 complexed by a...” PMID 31831560 ↗ Dec 2019 |